Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvogen And Yas Strike MENA Licensing Deal

Follows Yas Investment Agreement With Sister Company Alvotech

Executive Summary

Alvogen has struck a licensing deal with Yas Holding that gives the firm exclusive distribution rights to a portfolio of 28 generics in the Middle East and North Africa region from 2020.

You may also be interested in...



Deal Watch: AstraZeneca Continues Divestments By Offloading US/Canada Seroquel Rights

Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.

Alvotech Strikes $45m Deal With Yas

Alvotech has struck an investment deal worth $45m with Yas Holding that will give Yas a 2.5% stake in the business, as well as rights to sell three Alvotech biosimilars in the MENA region.

Zentiva Snaps Up Alvogen’s CEE Operations

Acquiring Alvogen’s operations in central and eastern Europe will strengthen private equity-backed Zentiva’s presence in both the generics and OTC markets.

Topics

Related Companies

UsernamePublicRestriction

Register

GB149385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel